Table 2:
Antibodies with Evidence of Heterogeneity for Associations with the Four EBV-related Cancers Evaluateda
| Marker and Array Sequence, by Stage of EBV Life Cycle | Ig Class | Heterogeneity across cancer types | Nasopharyngeal Carcinoma | Endemic Burkitt Lymphoma | EBV-positive classical Hodgkin Lymphoma | Extranodal NK/T-cell Lymphoma | ||||
|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|||||||||
| p-value for heterogeneityb | Fold Changec | p-valued | Fold Changec | p-valued | Fold Changec | p-valued | Fold Changec | p-valued | ||
|
| ||||||||||
| Latent | ||||||||||
| EBNA1 (synthetic peptide) | IgA | <.0001 | 2.2 | <.0001 | 1.0 | 0.91 | 1.0 | 0.28 | 1.1 | 0.1 |
| Early Lytic | ||||||||||
| BBLF1 YP_001129480.1-109516-109289 |
IgA | <.0001 | 1.2 | <.0001 | 1.0 | 0.09 | 1.2 | <.0001 | 1.1 | 0.1 |
| BBLF1 AFY97956.1-108555-108328 |
IgA | <.0001 | 1.2 | <.0001 | 1.0 | 0.43 | 1.2 | <.0001 | 1.1 | 0.15 |
| BMRF1 AFY97929.1-67486-68700 |
IgA | <.0001 | 1.5 | <.0001 | 1.0 | 0.44 | 1.0 | 0.51 | 1.1 | 0.01 |
| BMRF1 YP_001129454.1-67745-68959 |
IgA | <.0001 | 1.6 | <.0001 | 1.0 | 0.76 | 1.0 | 0.24 | 1.1 | 0.01 |
| LF2 YP_001129504.1-151808-150519 |
IgA | <.0001 | 1.8 | <.0001 | 1.0 | 0.66 | 1.0 | 0.97 | 1.0 | 0.94 |
| Thymidine kinase YP_001129497.1-133399-131576 |
IgA | <.0001 | 1.5 | <.0001 | 1.0 | 0.79 | 1.0 | 0.07 | 1.0 | 0.48 |
| Early Lytic | ||||||||||
| BBLF1 YP_001129480.1-109516-109289 |
IgA | <.0001 | 1.2 | <.0001 | 1.0 | 0.09 | 1.2 | <.0001 | 1.1 | 0.1 |
| BBLF1 AFY97956.1-108555-108328 |
IgA | <.0001 | 1.2 | <.0001 | 1.0 | 0.43 | 1.2 | <.0001 | 1.1 | 0.15 |
| BMRF1 AFY97929.1-67486-68700 |
IgA | <.0001 | 1.5 | <.0001 | 1.0 | 0.44 | 1.0 | 0.51 | 1.1 | 0.01 |
| BMRF1 YP_001129454.1-67745-68959 |
IgA | <.0001 | 1.6 | <.0001 | 1.0 | 0.76 | 1.0 | 0.24 | 1.1 | 0.01 |
| LF2 YP_001129504.1-151808-150519 |
IgA | <.0001 | 1.8 | <.0001 | 1.0 | 0.66 | 1.0 | 0.97 | 1.0 | 0.94 |
| Thymidine kinase YP_001129497.1-133399-131576 |
IgA | <.0001 | 1.5 | <.0001 | 1.0 | 0.79 | 1.0 | 0.07 | 1.0 | 0.48 |
| Late Lytic | ||||||||||
| BPLF1 CAA24839.1-71527-62078-2 |
IgA | <.0001 | 1.3 | <.0001 | 1.0 | 0.46 | 1.1 | 0.006 | 1.1 | 0.1 |
| BVRF1 YP_001129499.1-133954-13566 |
IgA | <.0001 | 1.3 | <.0001 | 1.0 | 0.18 | 1.0 | 0.84 | 1.1 | 0.1 |
| Latent | ||||||||||
| LMP1 AFY97906.1-168167-168081 |
IgG | <.0001 | 1.4 | <.0001 | 1.1 | <.0001 | 1.1 | 0.02 | 1.1 | 0.003 |
| EBNA3A AFY97915.1-80252-82747 |
IgG | 0.04 | 1.1 | 0.01 | 1.1 | <.0001 | 1.1 | 0.004 | 1.3 | <.0001 |
| Immediate Early Lytic | ||||||||||
| BRLF1 YP_001129468.1-93725-91908 |
IgG | <.0001 | 1.6 | <.0001 | 1.1 | 0.002 | 1.1 | 0.01 | 1.3 | 0.001 |
| BZLF1 YP_001129467.1-90855-90724 |
IgG | <.0001 | 1.7 | <.0001 | 1.2 | <.0001 | 1.1 | 0.004 | 1.1 | 0.03 |
| BZLF1 YP_001129467.1-91697-91197 |
IgG | <.0001 | 1.4 | <.0001 | 1.1 | 0.1 | 1.1 | 0.01 | 1.2 | <.0001 |
| BZLF1 CAA24861.1-102338-102210 |
IgG | 0.002 | 1.4 | <.0001 | 1.3 | <.0001 | 1.1 | 0.003 | 1.2 | 0.01 |
| Early Lytic | ||||||||||
| BALF2 YP_001129510.1-165796-162410-1 |
IgG | <.0001 | 1.5 | <.0001 | 1.1 | <.0001 | 1.1 | 0.0001 | 1.3 | <.0001 |
| BGLF2 YP_001129486.1-115415-114405 |
IgG | <.0001 | 1.9 | <.0001 | 1.1 | 0.01 | 1.0 | 0.08 | 1.0 | 0.31 |
| BHRF1 YP_001129442.1-42204-42779 |
IgG | 0.004 | 1.2 | <.0001 | 1.3 | <.0001 | 1.1 | 0.0001 | 1.1 | 0.01 |
| BLLF3 YP_001129459.1-76320-75484 |
IgG | <.0001 | 1.6 | <.0001 | 1.1 | 0.01 | 1.1 | 0.0003 | 1.1 | 0.05 |
| BMRF1 YP_001129454.1-67745-68959 |
IgG | <.0001 | 1.4 | <.0001 | 1.4 | <.0001 | 1.1 | 0.005 | 1.2 | <.0001 |
| BMRF1 AFY97929.1-67486-68700 |
IgG | <.0001 | 1.3 | <.0001 | 1.4 | <.0001 | 1.1 | 0.003 | 1.2 | 0.0002 |
| EAD_p47 (synthetic peptide) | IgG | <.0001 | 3.5 | <.0001 | 2.0 | <.0001 | 1.1 | 0.05 | 1.5 | 0.008 |
| LF2 YP_001129504.1-151808-150519 |
IgG | <.0001 | 1.9 | <.0001 | 1.0 | 0.1 | 1.1 | 0.001 | 1.1 | 0.23 |
| Thymidine kinase YP_001129497.1-133399-131576 |
IgG | <.0001 | 1.4 | <.0001 | 1.1 | 0.0005 | 1.2 | <.0001 | 1.2 | 0.0003 |
| Late Lytic | ||||||||||
| BBRF1 YP_001129476.1-102746-104587 |
IgG | <.0001 | 1.3 | <.0001 | 1.0 | 0.55 | 1.2 | <.0001 | 1.1 | 0.01 |
| BcLF1 AFY97965.1-125044-120899-1 |
IgG | 0.001 | 1.3 | <.0001 | 1.2 | <.0001 | 1.2 | <.0001 | 1.2 | 0.01 |
| BcLF1 CAA24794.1-137466-133321-1 |
IgG | 0.002 | 1.3 | <.0001 | 1.1 | <.0001 | 1.2 | <.0001 | 1.1 | 0.03 |
| BcLF1 YP_001129493.1-126005-121860-1 |
IgG | 0.008 | 1.2 | <.0001 | 1.2 | <.0001 | 1.2 | <.0001 | 1.1 | 0.15 |
| BFLF2 YP_001129443.1-44763-43807 |
IgG | 0.005 | 1.3 | <.0001 | 1.1 | 0.01 | 1.1 | 0.0001 | 1.0 | 0.41 |
| BFRF1 YP_001129446.1-46719-47729 |
IgG | <.0001 | 1.4 | <.0001 | 1.1 | 0.0002 | 1.1 | 0.0004 | 1.1 | 0.02 |
| BPLF1 YP_001129449.1-59370-49906-2 |
IgG | <.0001 | 1.3 | <.0001 | 1.1 | <.0001 | 1.1 | 0.0002 | 1.1 | 0.03 |
| BVRF1 YP_001129499.1-133954-135666 |
IgG | <.0001 | 1.3 | <.0001 | 1.3 | <.0001 | 1.0 | 0.18 | 1.2 | 0.001 |
a
Table is ordered by viral life cycle, followed by immunoglobulin type and viral protein in alphabetical order
b
P value denotes whether each marker’s effect on a given cancer significantly varies across the four cancer types after adjusting for sex, age group, and g eographic region. P value <0.05 is considered statistically significant.
c
All fold-change values are based on log2 scale.
d
P value is corresponding to t-test. P value <0.05 is considered statistically significant.